Consider the Role of Ongentys and Kynmobi for Parkinson’s Disease

December 2020

Ongentys (opicapone) and Kynmobi (apomorphine) will add to the growing list of new meds for Parkinson’s disease.

They’re for “off” episodes...when symptoms (tremor, etc) return between carbidopa/levodopa doses, especially as Parkinson’s progresses.

Optimize carbidopa/levodopa first...such as with more frequent dosing. Put the role of the new meds in perspective.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Venous Thromboembolism Answer Common Questions About VTE Treatment
Diabetes Meds Don’t Jump to SGLT2 Inhibitors for Patients WithOUT Diabetes
Benzodiazepines Consider Exit Strategies to Limit Use of Benzodiazepines
Practice Help Patients Navigate Mobile Health Apps
Pregnancy Educate Pregnant Moms About Treating Pain or Fever
Contraceptives Watch for Twirla, a New Contraceptive Patch
Parkinson's Disease Consider the Role of Ongentys and Kynmobi for Parkinson’s Disease
Vaccines Ensure Patients Get Recommended Meningococcal Vaccines
Alcohol Answer Questions About Hangover Remedies
Infectious Diseases Understand Roles of Remdesivir and Dexamethasone for COVID-19
Hemorrhage Feel Comfortable Sticking With NovoSeven RT Over Sevenfact